The outcomes of patients with lung cancer have improved significantly in recent years, largely due to the treatment targeting the cancer's specific genetic profile and the impact of immunotherapy, often in different groups of patients. In this interview, Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado Cancer Center, discusses the importance of considering multiple factors when deciding on clinical trials for patients. Oncology Data Advisor: When would you recom...

Recently, the FDA granted approval to cemiplimab (Libtayo®, Regeneron Pharmaceuticals) for the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) who were previously treated with a hedgehog pathway inhibitor (HHI) or who are ineligible for HHI therapy. In this interview, Karl Lewis, MD, Professor of Medical Oncology at the University of Colorado Anschutz Medical Campus and one of the investigators of Study 1620 (NCT03132636), on which the approval was based, spe...